![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 11, 2025
Grant updates; engineering and cancer research; Spring Group Meeting and ASCO highlights
June 11, 2025
The group is recognizing Dr. Schiller for her sustained commitment to mentoring early- and mid-career investigators in cancer medicine and in ECOG-ACRIN
June 11, 2025
The changes broaden eligibility and clarify treatment planning details in this phase 2 trial testing daratumumab-hyaluronidase to eliminate minimal residual disease after initial chemotherapy
June 11, 2025
Researchers with the ECOG-ACRIN Cancer Research Group presented a number of research findings at the 2025 ASCO Annual Meeting
June 11, 2025
Summaries and links to timely information about research results presented at medical meetings, recognition of research leaders, and more
April 24, 2025
An update on the Group's activity; a new Central Biorepository and Pathology Facility director; a preview of key Group Meeting sessions
April 24, 2025
Summaries of recently published ECOG-ACRIN research results
March 21, 2025
An update on the NCTN Grant; upcoming Group Meeting highlights; a perspective on the mistrust of science
March 21, 2025
Summaries of recently published ECOG-ACRIN and PrECOG research results
March 21, 2025
Summaries and links to timely information about research results presented at medical meetings, recognition of research leaders, and more
February 19, 2025
The co-chairs highlight the immense value of Cooperative Group cancer research and the importance of its continued funding
February 19, 2025
Patient-reported outcomes research has led to many discoveries that have influenced current research priorities and the way the Group designs its trials